Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Developmental follow-up, surveillance and support at the age of 4 years: a best practice guide from the British Association for Neonatal Neurodevelopmental Follow-Up.

Archives of disease in childhood. Fetal and neonatal edition·2026

Same author

Translational findings support regimen selection for first-in-human study of ubamatamab (MUC16 × CD3 bispecific antibody) in patients with recurrent ovarian cancer.

Clinical and translational science·2024

Same author

A PD-1-targeted, receptor-masked IL-2 immunocytokine that engages IL-2Rα strengthens T cell-mediated anti-tumor therapies.

Cell reports. Medicine·2024

Same author

Redesigning culturally tailored intervention in the precision health era: Self-management science context.

Nursing outlook·2022

Same author

Hypoxia Inducible Factor-1α binds and activates γ-secretase for Aβ production under hypoxia and cerebral hypoperfusion.

Molecular psychiatry·2022

Same author

Generation of T-cell-redirecting bispecific antibodies with differentiated profiles of cytokine release and biodistribution by CD3 affinity tuning.

Scientific reports·2021

Search research articles

Related Experiment Video

Updated: Nov 4, 2025

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells

Published on: May 12, 2023

Targeting Solid Tumors Using CD3 Bispecific Antibodies.

Alison Crawford¹, Danica Chiu²

¹Regeneron Pharmaceuticals, Inc., Tarrytown, New York. Alison.Crawford@regeneron.com.

Molecular Cancer Therapeutics

|May 28, 2021

Summary

Recent advances in T cell-engaging CD3 bispecific antibodies show promise for solid tumors. Overcoming resistance mechanisms is key to developing effective combination immunotherapies for cancer treatment.

More Related Videos

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity

Published on: July 12, 2018

Related Experiment Videos

Last Updated: Nov 4, 2025

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells

Published on: May 12, 2023

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity

Published on: July 12, 2018

Area of Science:

Oncology
Immunology
Biotechnology

Background:

Cancer immunotherapies have advanced significantly, particularly T cell-directed therapies like CD3 bispecific antibodies and CAR T cells.
These therapies have demonstrated potent efficacy against hematologic malignancies.
Their application to solid tumors remains a significant challenge.

Purpose of the Study:

To discuss recent advancements in T cell-engaging CD3 bispecific antibodies for solid tumors.
To explore potential mechanisms of resistance to these therapies in solid tumors.
To outline future prospects and strategies for overcoming resistance.

Main Methods:

Review of recent scientific literature on T cell-engaging CD3 bispecific antibodies.
Analysis of mechanisms of immune evasion in solid tumor microenvironments.
Discussion of therapeutic strategies and combination approaches.

Main Results:

T cell-engaging CD3 bispecific antibodies are a rapidly developing area for solid tumor treatment.
Solid tumors present unique challenges and mechanisms of immune evasion.
Understanding these mechanisms is crucial for therapeutic success.

Conclusions:

Further research into solid tumor immune evasion is necessary.
Development of strategies to overcome resistance is critical for advancing CD3 bispecific antibody therapy.
Informed therapeutic combinations will be essential for future cancer treatment.